Psychiatry

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

GH Research's phase 2b trial found GH001, an inhalable 5-MeO-DMT treatment, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

A new study found stimulant use in children dropped 19% early in the pandemic but rebounded, with the 2022 Adderall shortage prompting shifts to alternatives.

The FDA approved updated labeling for viloxazine ER capsules as an ADHD treatment, adding lactation data and details on serotonin 5-HT2C receptor activity.

Women experience more severe early PTSD symptoms than men, with re-experiencing and avoidance clusters being strongest. Men showed stronger anxious arousal patterns.

A study found depressive symptoms in older individuals with normal cognition were linked to amyloid pathology in APOE ε4 noncarriers but not carriers.

A new study showed sedative, hypnotic, and anxiolytic use disorder diagnoses rose 3- to 5-fold from 2001–2019 among adolescents and young adults.

A new study identified psychiatric, neurological, and somatic comorbidities of intermittent explosive disorder.

Mindfulness eased opioid cravings in OUD patients on buprenorphine but showed no added benefit over recovery support for abstinence, substance use, or anxiety.

The FDA approved esketamine (SPRAVATO) nasal spray as the first monotherapy for adults with TRD, showing rapid efficacy at 4 weeks.

A new study shows that employee stress improves when using a mindfulness meditation app for under or above 5 minutes (the more effective option).

Despite the surge in telemental health use in patients with schizophrenia, fewer people in racial or ethnic minority groups had a telemental health visit compared to White people.

Boehringer Ingelheim’s phase 3 trial of iclepertin for cognitive impairment in schizophrenia failed to meet primary and secondary endpoints, showing no significant effects.

A new study showed ADHD incidence trends fluctuated between 2016-2023, with adult diagnoses rising post-COVID-19 and adolescent rates remaining stable after an initial decline.

A study showed age and sex perform better at identifying the risk for opioid use disorder than candidate genetic variants.

A new study found that depression prevalence among older adults was greater for those who were 65 – 69 years old.

SP-624, a SIRT6 activator, showed promise in an exploratory study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.

New research reveals that frequent social media use, especially active use of platforms such as TikTok and Facebook, is linked to greater irritability levels.

A recent study showed expression profiles of amacrine cells, the interneurons within the retina, were enriched in schizophrenia genetic risk factors.

Individuals with stable schizophrenia struggle to recognize facial emotions such as sadness, disgust, and anger—but not happiness—which may impact social interactions.

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.

A study found intimate partner violence significantly lowers women's psychosocial well-being across finances, health, and relationships, but not men's.

Glutamatergic medications show promise for OCD & related disorders, reducing Y-BOCS scores.

A study found that the protein ADM significantly mediates loneliness' link to cardiovascular disease, stroke, dementia, and mortality, emphasizing loneliness’ health risks.

A recent study found individuals released from incarnation had a 10-fold greater prevalence of suicide mortality compared with the general population.

This Psychiatry Month in Review features promising phase 3 data, what is moving in the pipeline, and where the psychiatry field is heading into 2025.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.